



I hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Box Sequence, Washington, D.C. 20231 on the date shown below.

Date: November 20, 2001

By: Carol A. See

Carol A. See

PATENT

Docket No. GC450-US D1

4
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

De Buyl et al.)

Serial No.: 09/909,207)

Filed: July 19, 2001)

For: Xylanase, Microorganisms Producing it,)
DNA Molecules, Methods for Preparing)
this Xylanase and Uses of the Latter)

Group Art Unit: 1631

Examiner: Unassigned

STATEMENT OF SAMENESS

BOX SEQUENCE

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(d), the computer readable copy of the sequence listing, and the paper copy submitted herewith in the above application are believed to be the same. The present submission contains no new matter relative to the application as originally filed.

Respectfully submitted,

Date: 11/20/01

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304-1013
Tel: 650-846-7620
Fax: 650-845-6504

Lynn Marcus-Wyner
Lynn Marcus-Wyner
Registration No. 34,869



hereby certify that this correspondence is being deposited with the US Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Box Sequence, Washington, D.C. 20231, on the date shown below.

Date: November 20, 2001

By: Carol A. See

Carol A. See

PATENT

Docket No. GC450-US-D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

De Buyl et al.

Serial No.: 09/909,207

Filed: July 19, 2001

For: Xylanase, Microorganisms Producing it,
DNA Molecules, Methods for Preparing)
this Xylanase and Uses of the Latter)

Group Art Unit: 1631

Examiner: Unassigned

**TRANSMITTAL LETTER FOR NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

BOX SEQUENCE

Commissioner for Patents

Washington, D.C. 20231

Sir:


In complete response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 21, 2001, enclosed please find:

- ☐ a Combined Declaration and Power of Attorney signed by the inventor(s) and the surcharge of \$130.00 as set forth in 37 C.F.R. § 1.16(e);
- ☐ Petition for a _____ Month Extension of Time;
- ☐ Assignment document, Form PTO-1595, and the \$40.00 Assignment Recording Fee;
- ☐ Revocation & New Power of Attorney;

- ☒ Preliminary Amendment
- ☒ Statement of Sameness
- ☒ Paper copy of Sequence Listing (12 pages)
- ☒ Diskette copy of Sequence Listing
- ☐ Request for Use of an Identical Computer Readable Form in Another Application Under 37 CFR § 1.821(e);
- ☒ Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures (copy of Notice to be returned with response);
- ☐ Form PTO-1533 (copy of Notice to be returned with response); and
- ☐ Other: _____

Respectfully submitted,

Date: November 20, 2001


Lynn Marcus-Wyner
Registration No. 34,869

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7620
Fax: 650-845-6504



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/909,207	07/19/2001	Eric De Buyl	GC450-D1-US

Genencor International, Inc.
925 Page Mill Road
Palo Alto, CA 94034-1013



CONFIRMATION NO. 1260

FORMALITIES LETTER



OC000000006589034

Date Mailed: 09/21/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE